• Policy
• Yoon’s transition team prepares for digital platform govnt
• by Lee, Jeong-Hwan Mar 25, 2022 05:48am

• Policy
• Corona tx Largevrio has been urgently approved
• by Lee, Hye-Kyung Mar 24, 2022 05:54am

• Opinion
• [Reporter’s View] Specific healthcare plans are required
• by Lee, Jeong-Hwan Mar 24, 2022 05:54am

• Policy
• Ahn to tap on “domestic production of Paxlovid generic”
• by Lee, Jeong-Hwan Mar 24, 2022 05:54am

• Policy
• The price of Biktarvy will be lowered next month through PVA
• by Lee, Jeong-Hwan Mar 24, 2022 05:54am

• Company
• Why Vemlidy's patent dispute took 3 years to win the 1st tri
• by Kim, Jin-Gu Mar 24, 2022 05:54am

• Policy
• EUA of Lagevrio imminent…interest focused on its treatment
• by Lee, Jeong-Hwan Mar 23, 2022 05:51am

• Opinion
• [Reporter's view] Our attitude toward personalized txs
• by Eo, Yun-Ho Mar 23, 2022 05:51am

• Company
• Samsung Bioepis makes ₩847 billion expanding overseas
• by Chon, Seung-Hyun Mar 23, 2022 05:51am

• Company
• Gov purchased ₩200 billion worth of COVID-19 vaccines
• by Chon, Seung-Hyun Mar 23, 2022 05:51am